Cure My Disease

Don't miss your cure!

 Log in / Sign up

Five new drugs aim to tame painful skin condition

NCT ID NCT03827798

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests five different investigational drugs (iscalimab, LYS006, MAS825, remibrutinib, and ianalumab) in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to see if these drugs reduce abscesses and inflammatory nodules by at least 50% without increasing draining tunnels. Participants are randomly assigned to receive a drug or a placebo, and neither they nor their doctors know which they get.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

248 people

The number who actually took part.

Started

Feb 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved * Minimal body weight of 50 kg * Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule Exclusion Criteria: * Use of other investigational drugs at the time of screening or before * Women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception * Pregnant or lactating women Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Advanced Medical Research

    Sandy Springs, Georgia, 30328, United States

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana, 46256, United States

  • Medical University of South Carolina MUSC

    Charleston, South Carolina, 29425, United States

  • NorthShore University Health System

    Evanston, Illinois, 60201, United States

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Brussels, 1070, Belgium

  • Novartis Investigative Site

    Prague, Prague 1, 11000, Czechia

  • Novartis Investigative Site

    Copenhagen, 2400, Denmark

  • Novartis Investigative Site

    Roskilde, 4000, Denmark

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Reims, 51100, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Frankfurt, 60590, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Schwerin, 19055, Germany

  • Novartis Investigative Site

    Pécs, Baranya, 7623, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Szeged, H 6725, Hungary

  • Novartis Investigative Site

    Kopavogur, 201, Iceland

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Groningen, 9713 GZ, Netherlands

  • Novartis Investigative Site

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, 08208, Spain

  • Novartis Investigative Site

    Manises, Valencia, 46940, Spain

  • Novartis Investigative Site

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Olympian Clinical Research

    Clearwater, Florida, 33609, United States

  • Park Avenue Dermatology PA

    Orange Park, Florida, 32073, United States

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania, 17033-0850, United States

  • University Of South Florida

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.